The therapeutic effects of naringenin on bronchial pneumonia in children

Yao, Wenli; Zhang, Xiaopeng; Xu, Feng; Cao, Chunxia; Liu, Tongtong; Xue, Yuanyuan

doi:10.1002/prp2.825

Cited by 23 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty studies involving 5,166 subjects (flavonoids group: 2636; control group: 2530) were included. Five eligible studies ( 20 – 24 ) investigated the efficacy of flavonoids in the common cold, 4 ( 25 – 28 ) in influenza, 5 ( 29 – 33 ) in COVID−19, 3 ( 34 – 36 ) in acute non-streptococcal tonsillopharyngitis, 1 ( 37 ) in acute rhinosinusitis, 7 ( 38 – 44 ) in acute bronchitis, 1 ( 45 ) in bronchial pneumonia, and 4 ( 46 – 49 ) in upper respiratory tract infections. In common cold, 5 RCTs with 503 patients were involved.…”

Section: Resultsmentioning

confidence: 99%

“…The risk of bias data for the included 30 RCTs was presented in Figure 2 . The randomization process was rated at high risk in 3 (10%) RCTs ( 30 , 45 , 48 ) because concealment of allocation sequence was not presented or open-label design. Besides, 2 (6.7%) RCTs ( 34 , 42 ) were rated at some concerns for the lack of details of the concealment and the difference in baseline data between groups; the remaining 25 (83.3%) RCTs were rated at low risk.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the bias of measurement of the outcome was rated at high risk in 4 (13.3%) RCTs ( 30 , 46 – 48 ) for that the outcome assessors were aware of the interventions. Regarding the bias of selection of the reported result, 10 (33.3%) RCTs ( 24 , 25 , 27 , 28 , 36 , 38 , 43 , 45 , 48 , 49 ) were rated at some concerns for no protocols or registrations. The remaining 20 (66.7%) RCTs were rated at low risk.…”

Section: Resultsmentioning

confidence: 99%

“…One RCT ( 45 ) investigated the efficacy and safety of flavonoids in bronchial pneumonia. Results were shown in Table 6 .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Yao

Zhang

Wang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThis meta-analysis aimed to investigate the efficacy and safety of flavonoids in treating viral acute respiratory tract infections (ARTIs).MethodsRandomized controlled trials (RCTs) were entered into meta-analyses performed separately for each indication. Efficacy analyses were based on changes in disease-specific symptom scores. Safety was analyzed based on the pooled data from all eligible trials, by comparing the incidence of adverse events between flavonoids and the control.ResultsIn this study, thirty RCTs (n = 5,166) were included. In common cold, results showed that the flavonoids group decreased total cold intensity score (CIS), the sum of sum of symptom intensity differences (SSID) of CIS, and duration of inability to work vs. the control group. In influenza, the flavonoids group improved the visual analog scores for symptoms. In COVID−19, the flavonoids group decreased the time taken for alleviation of symptoms, time taken for SARS-CoV−2 RT-PCR clearance, the RT-PCR positive subjects at day 7, time to achievement of the normal status of symptoms, patients needed oxygen, patients hospitalized and requiring mechanical ventilation, patients in ICU, days of hospitalization, and mortality vs. the control group. In acute non-streptococcal tonsillopharyngitis, the flavonoids group decreased the tonsillitis severity score (TSS) on day 7. In acute rhinosinusitis, the flavonoids group decreased the sinusitis severity score (SSS) on day 7, days off work, and duration of illness. In acute bronchitis, the flavonoids group decreased the bronchitis severity score (BSS) on day 7, days off work, and duration of illness. In bronchial pneumonia, the flavonoids group decreased the time to symptoms disappearance, the level of interleukin−6 (IL−6), interleukin−8 (IL−8), and tumor necrosis factor-α (TNF-α). In upper respiratory tract infections, the flavonoids group decreased total CIS on day 7 and increased the improvement rate of symptoms. Furthermore, the results of the incidence of adverse reactions did not differ between the flavonoids and the control group.ConclusionResults from this systematic review and meta-analysis suggested that flavonoids were efficacious and safe in treating viral ARTIs including the common cold, influenza, COVID−19, acute non-streptococcal tonsillopharyngitis, acute rhinosinusitis, acute bronchitis, bronchial pneumonia, and upper respiratory tract infections. However, uncertainty remains because there were few RCTs per type of ARTI and many of the RCTs were small and of low quality with a substantial risk of bias. Given the limitations, we suggest that the conclusions need to be confirmed on a larger scale with more detailed instructions in future studies.Systematic Review Registration:inplasy.com/inplasy-2021-8-0107/, identifier: INPLASY20218010

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…One RCT ( 45 ) investigated the efficacy and safety of flavonoids in bronchial pneumonia. Results were shown in Table 6 .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Yao

Zhang

Wang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…It is the main flavanone in grapefruit. Although COVID-19 pneumonia is different from bronchopneumonia, the latter being a bacterial infection [97], it is interesting to note that naringenin reportedly can alleviate bronchial pneumonia in children [98].…”

Section: Flavonoids-classification Structure and Anti-viral Activitiesmentioning

confidence: 99%

Nanotechnology Applications of Flavonoids for Viral Diseases

et al. 2021

View full text Add to dashboard Cite

Recent years have witnessed the emergence of several viral diseases, including various zoonotic diseases such as the current pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Other viruses, which possess pandemic-causing potential include avian flu, Ebola, dengue, Zika, and Nipah virus, as well as the re-emergence of SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) coronaviruses. Notably, effective drugs or vaccines against these viruses are still to be discovered. All the newly approved vaccines against the SARS-CoV-2-induced disease COVID-19 possess real-time possibility of becoming obsolete because of the development of ‘variants of concern’. Flavonoids are being increasingly recognized as prophylactic and therapeutic agents against emerging and old viral diseases. Around 10,000 natural flavonoid compounds have been identified, being phytochemicals, all plant-based. Flavonoids have been reported to have lesser side effects than conventional anti-viral agents and are effective against more viral diseases than currently used anti-virals. Despite their abundance in plants, which are a part of human diet, flavonoids have the problem of low bioavailability. Various attempts are in progress to increase the bioavailability of flavonoids, one of the promising fields being nanotechnology. This review is a narrative of some anti-viral dietary flavonoids, their bioavailability, and various means with an emphasis on the nanotechnology system(s) being experimented with to deliver anti-viral flavonoids, whose systems show potential in the efficient delivery of flavonoids, resulting in increased bioavailability.

show abstract

Anti‐inflammatory effects of natural products from vitamin C‐rich fruits

Chan,

Xiong,

Zhao

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

Inflammation is a crucial target for therapeutic interventions in many life‐threatening diseases, which sustains ongoing interest in the field of inflammation biology. Plant‐derived natural products, rich in phytochemicals, have been used as healing agents in several diseases since antiquity. These compounds exhibit antioxidant, anti‐inflammatory, and immunomodulatory properties, as well as gut microbiota modulation. They hold substantial potential as promising candidates for the development of novel strategies in the management of inflammation‐associated diseases. This study presents a comprehensive overview of the potential benefits given from administrating natural products (e.g., phenols, terpenes, flavonoids, and saccharides), with a particular emphasis on vitamin C‐rich fruits based on the high content of bioactive compounds with anti‐inflammatory properties. Apart from natural products, the gut microbiota acts a significant role in modulating the activation of inflammatory reaction. Deviations in its composition have been associated with various diseases. Furthermore, advancements in machine learning contribute to enhancing clinical outcomes in disease treatment. Therefore, this work provided some valuable insights in elaborating the therapeutic potential of vitamin C‐rich fruits, the role of probiotics as anti‐inflammatory agents, and the utilization of computer‐aided drug design techniques.

show abstract

The therapeutic effects of naringenin on bronchial pneumonia in children

Cited by 23 publications

References 31 publications

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Nanotechnology Applications of Flavonoids for Viral Diseases

Anti‐inflammatory effects of natural products from vitamin C‐rich fruits

Contact Info

Product

Resources

About